Damora Therapeutics, Inc. (DMRA) stock
DMRANasdaqPharmaceutical PreparationsFiscal year ends December 31
$22.56+0.06 (+0.29%)
Close on Nov 17, 2026Market cap $1.39BP/E 5.7Yield 0.00%
Damora Therapeutics cash
Cash and short-term investments held at the end of each period.
Damora Therapeutics's cash was $528.48M at Sep 30, 2026. For fiscal 2025 it was $257.62M, up 1717.5% from the year before. The highest annual figure on record is $257.62M in fiscal 2025.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $257.62M | +1717.5% |
| FY2024 | Dec 31, 2024 | $14.18M | -57.2% |
| FY2023 | Dec 31, 2023 | $33.15M | -45.0% |
| FY2022 | Dec 31, 2022 | $60.22M | -39.9% |
| FY2021 | Dec 31, 2021 | $100.19M | -38.8% |
| FY2020 | Dec 31, 2020 | $163.84M | +1321.6% |
| FY2019 | Dec 31, 2019 | $11.53M | -63.0% |
| FY2018 | Dec 31, 2018 | $31.13M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $528.48M | +6848.2% |
| Q2 FY2026 | Jun 30, 2026 | $540.52M | +5193.5% |
| Q1 FY2026 | Mar 31, 2026 | $532.90M | +4363.5% |
| Q4 FY2025 | Dec 31, 2025 | $257.62M | +1717.5% |
| Q3 FY2025 | Sep 30, 2025 | $7.61M | -61.3% |
| Q2 FY2025 | Jun 30, 2025 | $10.21M | -55.3% |
| Q1 FY2025 | Mar 31, 2025 | $11.94M | -56.1% |
| Q4 FY2024 | Dec 31, 2024 | $14.18M | -57.2% |
| Q3 FY2024 | Sep 30, 2024 | $19.68M | -55.5% |
| Q2 FY2024 | Jun 30, 2024 | $22.86M | -56.1% |
| Q1 FY2024 | Mar 31, 2024 | $27.17M | -49.0% |
| Q4 FY2023 | Dec 31, 2023 | $33.15M | -45.0% |
| Q3 FY2023 | Sep 30, 2023 | $44.18M | -36.1% |
| Q2 FY2023 | Jun 30, 2023 | $52.12M | -34.0% |
| Q1 FY2023 | Mar 31, 2023 | $53.25M | -43.1% |
| Q4 FY2022 | Dec 31, 2022 | $60.22M | -39.9% |
| Q3 FY2022 | Sep 30, 2022 | $69.08M | -32.4% |
| Q2 FY2022 | Jun 30, 2022 | $79.03M | -22.4% |
| Q1 FY2022 | Mar 31, 2022 | $93.60M | -15.2% |
| Q4 FY2021 | Dec 31, 2021 | $100.19M | -38.8% |
| Q3 FY2021 | Sep 30, 2021 | $102.14M | +19.7% |
| Q2 FY2021 | Jun 30, 2021 | $101.81M | +184.1% |
| Q1 FY2021 | Mar 31, 2021 | $110.33M | +157.9% |
| Q4 FY2020 | Dec 31, 2020 | $163.84M | +1321.6% |
| Q3 FY2020 | Sep 30, 2020 | $85.33M | +480.7% |
| Q2 FY2020 | Jun 30, 2020 | $35.84M | +15.1% |
| Q1 FY2020 | Mar 31, 2020 | $42.78M | – |
| Q4 FY2019 | Dec 31, 2019 | $11.53M | – |
| Q3 FY2019 | Sep 30, 2019 | $14.70M | – |
| Q4 FY2018 | Dec 31, 2018 | $31.13M | – |
See a number that looks wrong?